Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

The full scientific article, published in the journal Science, is available for the CAPRISA 004 trial. This double-blind, randomized controlled trial demonstrated that tenofovir gel used before and after sex reduced HIV acquisition by an estimated 39 percent among women in the trial, and by 54 percent among the women with high gel adherence.

External Links:

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

Year:

2010

Organization:

Science

Languages:

English

This website is made possible by the support of the American People through the United States Agency for International Development (USAID) under the Knowledge SUCCESS (Strengthening Use, Capacity, Collaboration, Exchange, Synthesis, and Sharing) Project. Knowledge SUCCESS is supported by USAID’s Bureau for Global Health, Office of Population and Reproductive Health and led by the Johns Hopkins Center for Communication Programs (CCP) in partnership with Amref Health Africa, The Busara Center for Behavioral Economics (Busara), and FHI 360. The contents of this website are the sole responsibility of CCP. The information provided on this website does not necessarily reflect the views of USAID, the United States Government, or the Johns Hopkins University. Read our full Security, Privacy, and Copyright Policies.